Direct-compression tablet manufacture with Compound Ephedra Powder Veterinary Grade API is assessed on a 10–20 kg pilot batch in a 25 L bin blender before transfer to a rotary tablet press with an 8–12 station turret. Because the botanical powder is cohesive and may exhibit hygroscopicity above 55% relative humidity, the formulation is pre-conditioned by drying at 40–50°C to a loss on drying of not more than 5.0% w/w before blending; moisture content is verified by the method in USP <731>. A representative screening formulation consists of 15.0% w/w API, 78.0% microcrystalline cellulose PH102, 4.0% crospovidone, 2.5% pregelatinized starch, and 0.5% magnesium stearate; the active marker is calculated as total ephedrine alkaloids, expressed as ephedrine hydrochloride, and must be assayed by HPLC using a method validated for linearity over 50–150% of the nominal concentration. Batch-to-batch variance in ephedrine alkaloid content is a critical scale-up risk, and the API certificate of analysis should report total ephedrine alkaloids by HPLC rather than total nitrogen by Kjeldahl, because non-alkaloid plant protein can overestimate potency. Blending is performed in a V-blender filled to 50–60% of gross capacity at 20–25 rpm for 15–25 min, and blend uniformity is confirmed by sampling ten positions and calculating acceptance value according to USP <905>. Compression is run at 10–14 kN main compaction force with 2–4 kN pre-compression, and tablet hardness is checked at 60–80 N by USP <1217>; friability is maintained at not more than 1.0% by USP <1216>. Because herbal extracts can soften under heat and pressure, press speed is restricted to 30–55 rpm on rotary machines until punch-tip temperature is confirmed below 40°C. The resulting tablets are uncoated immediate-release dosage forms; if coating is required for odour masking, a PVA-based film coat applied at 2.0–3.0% weight gain is preferred over hydroxypropyl methylcellulose systems that may increase disintegration time. Disintegration is tested by USP <701> in 0.1 M hydrochloric acid with a limit of NMT 15 min; dissolution screening uses USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 M HCl at 37.0±0.5°C. In jurisdictions where ephedrine-containing veterinary APIs are controlled, the final tablet must be released through a prescription-only veterinary medicine channel, and batch records must include a mass balance for ephedrine alkaloids.

What Limits Batch Homogeneity at Low Active Marker Loading in Medicated Premixes?

Feed-mill processing of compound ephedra powder for medicated premix manufacture is limited less by the mill itself than by particle-size mismatches between the herb powder and the carrier. When the API is milled to a D90 of 75–100 µm and the carrier coarse fraction D10 is above 300 µm, percolation segregation during auger transfer can produce assay coefficient of variation values above 8.0% after a nominally complete mix. The standard industrial control is not extended mixing time but geometric dilution in three stages, each using a separate mixer cleanout procedure. Laser diffraction analysis according to ISO 13320:2020 should be performed on the API and the carrier before each campaign; if the API span (D90−D10)/D50 exceeds 1.8, the premix is further classified or re-milled. Mixing is conducted in ribbon mixers or vertical cone mixers filled to 55–65% of rated capacity, with agitator speeds of 20–25 rpm for the first dilution stage; mixing time is determined by sampling at 5, 10, 15, and 20 min and stopping when the active marker coefficient of variation remains below 5.0% for two consecutive sampling points. High-volume premix lines often exhibit dust collection and electrostatic coating of the ribbon mixer walls; grounding the mixer to less than 1 MΩ resistance and adding 0.5–1.0% vegetable oil as a processing aid reduces dust but can reduce flow and must be recorded as a processing aid. The carrier may be wheat bran, ground corn cob, or calcium carbonate; calcium carbonate is preferred for dry outdoor storage because it does not promote the microbial growth observed with cereal carriers at water activity above 0.70. Each dilution stage is assayed by HPLC after acid extraction, and the final feed incorporation rate is calculated to deliver the approved daily ephedrine dose per kg body weight in the target species. It is critical to record the withdrawal period in food-producing species according to the marketing authorization or national residue control guidance; ephedrine alkaloids are prohibited or restricted in many jurisdictions, so only authorized prescription premix formulations may be compounded.

For veterinary compounding pharmacies and small-scale capsule lots, powder filling on tamping-pin capsule machines is sensitive to the form of silica dioxide used as a glidant; fumed silica at 0.2–0.5% w/w and colloidal silicon dioxide at 0.5–1.0% w/w are considered separately because their effects on blend flow and fill weight are not identical. Capsules containing compound ephedra powder are filled into size 1 or size 2 hard gelatin capsules only after the API blend is dried to an LOD below 4.0% w/w; residual moisture above this threshold can cause gelatin cross-linking over 3–6 months when the powder contains plant aldehyde residues. For this reason, HPMC capsules meeting the specifications of USP <2095> are often selected for stability. Fill weight control on dosator machines is verified at 5–10 minute intervals by weighing 10 filled capsules; a relative standard deviation of not more than 2.5% is the usual internal limit. Powder for oral administration is also packed as unit-dose sachets; the sachet film is a polyethylene/aluminium/paper laminate to prevent oxygen ingress, and residual oxygen in the headspace after sealing should not exceed 3.0% when the stability protocol includes an oxidation-sensitive marker.

When Terminal Sterilization Is Replaced by Aseptic Filtration in Injectable Ephedra Alkaloid Products

Aseptic filtration rather than terminal steam sterilization is selected when the multi-herb extract fraction contains heat-labile polysaccharides and the solution pH is above 5.0. The pH-dependent solubility of ephedrine is governed by its pKa of 9.6; at pH 5.0 the alkaloid is almost fully protonated, and aqueous solubility is highest. Buffering to pH 4.0–5.0 with acetate buffer is therefore used for injectable solutions containing 5–30 mg/mL total ephedrine alkaloids calculated as ephedrine hydrochloride. The solution is filtered through 0.22 µm PVDF membrane cartridges after pre-filtration through 0.45 µm polypropylene depth filters; filter integrity is tested by bubble point or pressure decay as described in the manufacturer's validation file and referenced to ISO 29463-1:2017 for high-efficiency filtration. Filling into amber Type I borosilicate vials is performed under Grade A aseptic conditions with Grade B background; vial closure integrity is verified by dye ingress at 100% of the lower limit specified in USP <1207>. Published multi-herb terminal sterilization data for this exact compound powder are limited; therefore each formulation must be validated under a product-specific load. If terminal moist-heat sterilization at 121.1°C for 15 min is evaluated, loaded-chamber temperature mapping per ISO 17665-1:2006 and post-sterilization assay are required; acceptance is no more than 5.0% loss of ephedrine marker and no visible colour change. Oxygen-sensitive formulations may be flushed with nitrogen before sealing; dissolved oxygen is maintained below 1.0 ppm by sparging with 0.2 µm filtered nitrogen for at least 15 min in the bulk tank. Sodium chloride is used to adjust tonicity to 280–320 mOsm/kg measured by freezing point depression. Sterile API must comply with USP <71> sterility test and USP <85> bacterial endotoxins; final injection limit is 0.5 EU/mg for small-volume intravenous injections. Sub-visible particulate matter is controlled by USP <787> for small-volume injections, and the container glass is tested to USP <660> for hydrolytic resistance. Because ephedrine is a controlled substance in many supply-chain jurisdictions, the injection manufacturing area must maintain a chain-of-custody record for the API and for in-process rejects.

Drinking Water Solubility Limits at Alkaline pH and Pipe Biofilm Compatibility

Medicated drinking water prepared from compound ephedra powder is vulnerable to precipitation when the source water pH is between 7.8 and 8.5 and the alkalinity exceeds 250 mg/L as CaCO3. Under these conditions the free base fraction increases, and undissolved alkaloid-lignin complexes accumulate in nipple drinker lines, pressure regulators, and 50 µm mesh filters. The solution is prepared by adding citric acid anhydrous at 1.0–2.5 g/L to bring the pH to 5.0–5.5 before the API is added; if sodium bicarbonate buffer is used for pH adjustment, the final solution must be protected from light because carbonate-mediated oxidation of ephedrine is a known degradation pathway in aqueous alkaline media. The use of chlorinated water at 0.5–1.0 mg/L free chlorine does not necessarily inactivate the API, but the active marker may be oxidized during 24 h storage; therefore the working solution is prepared daily and remains stable for 24 h when the storage tank is closed and held at 15–25°C. In-line filtration through 50–100 µm stainless steel or nylon filters is installed at each nipple drinker or bell drinker circuit to trap plant fibres larger than 100 µm. Biofilm control in the water line is a separate critical point: plant polysaccharides in the formula provide nutrient for Pseudomonas spp.; cleaning after each dosing cycle uses 0.5% citric acid for 30 min followed by 0.1% peracetic acid for 15 min and a clean-water rinse. Microbial quality of the production water should meet the parameters of Directive 98/83/EC; for veterinary medicated water, Regulation (EU) 2019/6 requires that the product is administered in accordance with the authorized species-specific instructions.

When direct compression is not feasible because the API exhibits Carr index values above 30% or discharge from the hopper is interrupted by ratholing, granulation is introduced as a deliberate particle-engineering step. Roller compaction is preferred over wet granulation when the input lot contains water-soluble extractives that become sticky at elevated moisture. The dry granulation process uses a roller compactor with 150 mm roll diameter, roll gap 2–4 mm, and hydraulic pressure 40–80 bar; ribbons are milled through a 1.0 mm screen with a rotor speed of 50–80 rpm to obtain granules with a median diameter of 400–800 µm. Slugs are screened and the oversized fraction above 1.4 mm is re-milled. Granule flow is measured by a flowmeter based on ISO 4324 or by the method in USP <1174>; a mass flow rate of 10–25 g/s through a 15 mm orifice is used as a release indicator. If wet granulation is required for dose uniformity, the binder solution is polyvinylpyrrolidone K30 at 3.0–5.0% w/w in purified water, added at a spray rate of 20–40 g/min in a high-shear mixer with impeller speed 200–300 rpm; the granulate is dried in a fluid bed at an inlet temperature of 55–60°C until residual moisture is 3.0–5.0% w/w. These granules are then filled into sachets or used as intermediate for tablet compression. The terminal powder or granule must pass sieve analysis; fines below 75 µm should be not more than 20.0% of the total mass to prevent segregation in the packaging line. In all pharmaceutical granulation operations for this API, the equipment contact surfaces are cleaned by a validated process because ephedrine residues are controlled substances in many supply-chain jurisdictions and cross-contamination limits must follow the appropriate regulatory guidance.